Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Key progress has been achieved in many clinical trials of Abexinostat.

Jianghuzhiyuan/PharmaSourcesJune 27, 2023

Tag: HDAC inhibitor , Anti-tumor , Hematologic Tumor

PharmaSources Customer Service